The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Advancements at ASH 2017 that are directly relevant to patients
There were many advancements presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, that are directly relevant to patients. In this interview, the 2017 ASH President, Kenneth Anderson, MD, of the Dana-Farber Cancer Institute, Boston, MA, eloquently describes the two overarching themes of the meeting and, along with examples, highlights the impacts that these advances will have for the treatment of hematological malignancies.
